Inno assembling biotech plant in Nilai

SEREMBAN: The modules for building Malaysia's first current Good Manufacturing Practice (cGMP) biopharmaceutical production plant have arrived at the Inno Biologics site in Nilai near here.  

“This first cGMP plant represents one of the investments of the Government in the biotech industry,” Science, Technology and Innovation Minister Datuk Seri Dr Jamaludin Jarjis told reporters following a ceremony to mark the arrival of the modules last Friday. 

Inno Biologics chairman Tan Sri Dr Ahmad Zaharudin Idrus said the cGMP plant was located within the company's biotech facility, which also housed its headquarters, supporting facilities and laboratories.  

The construction of the modules for the plant was carried out in Germany and the reassembling has already begun here. 

“Over RM50mil have been invested in the plant, which will create new opportunities for Malaysians to venture into the production of biopharmaceuticals. The cGMP plant has signified a new milestone for biotechnology development in the country,” he said. 

Pharmaplan International of Germany was appointed Inno Biologics' contractor and was responsible for shipping the entire modular plant from Germany to Malaysia. 

It will be ready for testing, commissioning and validation once reassembled and will be scheduled to commence production in 2007. 

“With this facility, contract manufacturing will be offered to pharmaceutical and biopharmaceutical companies, as well as research institutes for the production of novel biologics for clinical testing,” said Zaharudin.  

Inno Biologics is the flagship company of Inno Bio Ventures Sdn Bhd, a Ministry of Finance incorporated company, with close affiliation to the Science, Technology and Innovation Ministry. – Bernama  

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3

Next In Business News

Malaysia Airlines extends flexibility for passengers to change travel dates
MAA: Vehicle sales up 33% to 63,878 units in March
FBM KLCI ends flat on lack of fresh catalysts
Grab considering secondary Singapore listing after US SPAC merger - sources
UEM Edgenta denies allegations, claims against its subsidiary by AZSB
Bank Negara revises foreign exchange notices
Tencent raises US$4.2bil in its second major bond deal in a year
World stocks near record highs as China, U.S. data back global recovery hopes
Oil steady climbs to four-week high on strong China data, demand revival
Sinopharm to inject US$4.6 bln vaccine assets into unit Tiantan Biological

Stories You'll Enjoy